Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Penumbra (PEN) stock in plain English

Free brief · no signupStart here
PENPublished Nov 14, 2026
Penumbra Inc
Healthcare · Medical Devices
Manufactures aspiration thrombectomy systems and neurovascular access tools for hospital catheterization labs.
Assets:
Roseville campusMain production and distribution center located in California
Lightning platformFlagship computer-controlled clot aspiration technology
4,200 workersGlobal staff supporting specialized catheter manufacturing and sales
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

74
OPS ScoreOperating finances
Latest quote
-0.18%$320.01
$12.61B
80.6×
$1.56B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PEN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Penumbra (PEN) do?

Penumbra Inc (PEN) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures aspiration thrombectomy systems and neurovascular access tools for hospital catheterization labs. Engineers computer-assisted aspiration systems that remove blood clots from neurovascular and peripheral blood vessels. It is worth $12.61B on the market and sold $1.56B over the last year.

Market cap
$12.61B
P/E ratio
80.6×
Annual sales
$1.56B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 14, 2026

Brands and businesses behind PEN

  • Lightning: Computer-assisted clot removal system sold to vascular specialists for stroke and embolism treatments.
  • Indigo System: Aspiration thrombectomy device sold to hospitals for clearing clots in peripheral arteries and veins.
  • Ruby Coil: Detachable platinum coil implant used by neurosurgeons to pack and seal brain aneurysms.
  • REAL System: Virtual reality therapy hardware and software leased to rehabilitation clinics for patient physical therapy.

PEN’s flags, in plain English

Each flag is a number from Penumbra’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 5.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 13% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 66.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Priced for Perfection

Priced at 80.6 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about PEN

How big is Penumbra?

Penumbra’s market cap is $12.61B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.56B: what customers paid the company over the last year, before any costs.

What is PEN’s P/E ratio?

PEN’s P/E ratio is 80.6×. Investors pay about 80.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with PEN?

Large cardiovascular device makers sell rival thrombectomy tools directly to the same hospital catheter labs. That is one risk on Penumbra’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Penumbra’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PEN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card